Natera, Inc. - Common Stock (NQ:NTRA)

Natera Submits Signatera™ CDx PMA to FDA

February 02, 2026

Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation

January 28, 2026

Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care

January 26, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

2 Cash-Producing Stocks to Consider Right Now and 1 Facing Headwinds

January 25, 2026

Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer

January 21, 2026

Natera’s Fetal Focus™ Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting

January 20, 2026

GRAIL Surges as Canaccord Genuity Sets Ambitious $105 Price Target Following Robust 2025 Growth

January 13, 2026

In a resounding vote of confidence for the future of multi-cancer early detection (MCED), Canaccord Genuity reiterated its "Buy" rating for GRAIL (Nasdaq: GRAL) on Tuesday, January 13, 2026, setting an...

Via MarketMinute

Adaptive Biotechnologies Surges as Preliminary 2025 Results Signal a Turning Point in MRD Commercialization

January 13, 2026

Shares of Adaptive Biotechnologies (NASDAQ: ADPT) soared on Tuesday, January 13, 2026, after the life sciences company announced preliminary fourth-quarter and full-year 2025 financial results that...

Via MarketMinute

Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling

January 13, 2026

Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA

January 12, 2026

Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth

January 11, 2026

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining...

2 Cash-Heavy Stocks to Keep an Eye On and 1 We Question

January 10, 2026

Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer

Stay updated with the stocks that are on the move in today's after-hours session. ↗

January 07, 2026

Via Chartmill

January 07, 2026

From Exelixis, Inc.

Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI

January 05, 2026

Natera Launches 21-Gene Fetal Focus™ Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP™ Technology

January 05, 2026

The Year-End Biotech Chill: Adaptive Biotechnologies Braces for J.P. Morgan Crucible Amid Market Sell-Off

December 30, 2025

As the final trading days of 2025 wind down, the biotechnology sector finds itself caught in a paradoxical "bifurcated" squeeze. While the broader indices have touched record highs this year, a sharp...

Via MarketMinute

3 Growth Stocks with Explosive Upside

December 28, 2025

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who...

Over the past six months, Natera has been a great trade, beating the S&P 500 by 24.2%. Its stock price has climbed to $235.65, representing a healthy 37.1% increase. This was partly thanks to its solid...

Topics Energy

3 Reasons We’re Fans of Natera (NTRA)

December 23, 2025

Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that can do all three for many years are often the...

Topics Stocks

3 Market-Beating Stocks Worth Your Attention

December 22, 2025

Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference

December 22, 2025

Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer

December 18, 2025

I-SPY 2 Publication in Nature Communications Shows Signatera™ Can Predict Treatment Response and Recurrence Risk in Early-Stage Breast Cancer

December 16, 2025

Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer

December 12, 2025

Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer

December 10, 2025

Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting

December 09, 2025

Natera Acquires Foresight Diagnostics

December 05, 2025

New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting

December 03, 2025

Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera™ at the San Antonio Breast Cancer Symposium

December 02, 2025